Our investigation of lot sp100540 includes: manufacturing review: review of information as reported, review of the device history records and complaint.
History.
Records associated with lot sp100540.
Results of evaluation: no failure detected.
Review of lot processing history and complaint history records for lot sp100540 was unremarkable.
There was no processing deviation or nonconformance related to the nature of this complaint.
The lot met qc criteria for release, including mechanical testing results.
As of (b)(6) 2018, no similar complaint has been reported to lifecell against lot sp100540.
As of (b)(6) 2018, of the (b)(4) devices released to finished goods for lot sp100540, (b)(4) devices were distributed with (b)(4) devices reported to be implanted.
Evaluation conclusion: known inherent risk of device.
Device not returned.
Based on our internal review of the device processing history, the lot met qc criteria for product release.
The event is unlikely related to strattice bps.
Lot sp100540 was aseptically processed, terminally sterilized within process parameters, and met qc release criteria.
No deviation was encountered in association with the reported event.
No other infection complaint has been reported to lifecell against lot sp100540.
[(b)(4) - follow up response recipient cultures (b)(6) 2018.
Pdf].
|
It was reported that a (b)(6) year old female patient underwent revision of right breast with strattice bps due to capsular contracture on (b)(6) 2018.
On (b)(6) 2018, the patient presented with post op infection resulting in surgical and medical intervention that day.
Cloudy serosanguineous fluid was found around the implant and strattice bps mesh.
There were no abscesses or hematoma.
Her implant was intact.
The pocket was washed out, a drain was placed, the patient was treated with antibiotics, and the strattice bps mesh was explanted along with the implant.
The patient has since recovered and was rescheduled for follow up procedure.
|